Debiopharm Announces First Patient Dosed in Investigator-initiated, Randomized Phase II, Open-label Clinical Trial for its Antiviral Alisporivir

Debiopharm | January 18, 2021

Debiopharm , a Swiss biopharmaceutical organization, reported the principal patient dosed in a investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The examination will be led by the AP-HP to assess the adequacy and wellbeing of the cyclophilin inhibitor in the therapy of beginning phase, hospitalized COVID-19 patients who don't need clinical ventilation and have not shown indications of intense respiratory distress syndrome. The essential goal of this 'proof-of-concept' preliminary is to assess the decrease in COVID-19 viral burden in alisporivir treated patients. The secondary objective includes the analysis of clinical and radiological efficacy, wellbeing and decency of the compound in addition to Standard of Care (SOC) contrasted with SOC alone. Patients in the investigational arm will get alisporivir either orally or by means of a nasogastric tube, at the portion of 600mg twice every day for 14 days during the preliminary drove by Prof. Jean-Michel Pawlotsky, virologist, Head of the Biology and Pathology Department of the Henri Mondor Hospital Group, Greater Paris University Hospitals. The trial, upheld by both the hospital group gathering and Debiopharm, will be done in numerous centers in France including the Henri Mondor Hospital Group.

Medical perceptions have indicated that viral infections , for example, COVID-19 can be life-threatening because of an overcompensation of the body's immune defense system. Part of the cyclophilin inhibitor class of antivirals, this macrocyclic cyclophilin inhibitor could end up being an important extra therapy to SOC because of its non-immunosuppressive nature.


Experiome Biotech Pvt Ltd is your destination for project dissertations, trainings, workshops, internships, thesis writing, project writing and many more biotech research and training needs.


Experiome Biotech Pvt Ltd is your destination for project dissertations, trainings, workshops, internships, thesis writing, project writing and many more biotech research and training needs.

Related News


Resilience Partners with a Major Pharmaceutical Company for Strategic Biomanufacturing

Resilience | February 20, 2023

National Resilience, Inc. (Resilience), a manufacturing company with a technology-focused mission to improve access to complex medications, recently announced a 10-year biomanufacturing partnership with a top pharmaceutical company for its portfolio of services in process and analytical development, drug substance manufacturing, and drug product manufacturing. The extensive agreement covers prospective biologic, vaccine, nucleic acid, cell, and gene therapy manufacturing. Resilience’s recently acquired facility in Cincinnati, Ohio, is its worldwide center of excellence to produce commercial medicinal products, and will deliver the first product as stipulated under the agreement. The development of complicated pharmaceuticals, such as cell and gene therapies, has not kept up with the rate of scientific advancements that are supporting them. Resilience brings together exceptional minds in science and engineering to bridge this gap with access to state-of-the-art technology. Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience, said, “The partnership announced today is a major milestone for Resilience.” He further added, “We are grateful to have this opportunity to work with our partner to deliver important, life-saving medicines to patients. We understand the trust placed with us to manufacture the medicine with the highest quality, regulatory compliance, and reliability. We are committed to maintaining a responsible manufacturing operation that exceeds the expectations of our partners and enables us to make a meaningful impact on global healthcare.” (Source – Business Wire) With the addition of this alliance to its expanding commercial portfolio, the company anticipates generating record revenues in 2023. About Resilience Resilience is a technology-focused biomanufacturing startup. The company intends to increase access to sophisticated medications. The firm is establishing a long-term network of cutting-edge, all-inclusive manufacturing solutions to guarantee that the therapies of today and the future may be produced efficiently, securely, and at scale. Resilience aims to continuously develop the science of biopharmaceutical manufacture and development, so their partners concentrate on the discoveries that enhance patients' lives and safeguard biopharmaceutical supply chains from future disruptions.

Read More


Twist Bioscience Announces Technology Early Access of eWGS Solution

Twist Bioscience Corporation | February 13, 2023

Twist Bioscience Corporation, a company that helps customers succeed by providing high-quality synthetic DNA on its silicon platform, recently announced technology early access to the Twist enhanced Whole Genome Sequencing (eWGS) solution for applications related to non-human gnomics at the Advances in Genome Biology and Technology 2023 General Meeting conducted in Hollywood, Florida. eWGS is a unique solution that allows researchers to collect simultaneous low-pass whole genome data as well as in-depth coverage of specific areas in a high-throughput and cost-effective workflow. The eWGS workflow begins with a modified Twist 96-plex library preparation kit, which prepares 96 samples in a single tube for sequencing. Following that, a single-tube 96-plex enrichment on an aliquot of the library is performed using a customized panel to enrich further targets that require additional coverage. The original and enhanced libraries are then merged into a single sequencer-ready pool with low whole genome coverage (0.5x to 4x) and high target-specific coverage. Researchers can tailor the coverage differential between low-pass and high-pass sites to their own needs. Preparing and enriching 96 samples for sequencing at once in a single pool enables a high-throughput workflow and may save costs by utilizing fewer materials and resources. Twist Bioscience’s co-founder and CEO Emily M. Leproust commented, “In agricultural genomics, researchers constantly have to make a tradeoff between cost and insight. Deep sequencing across entire genomes is cost prohibitive, forcing researchers to turn to less costly approaches like genotyping by sequencing, microarrays, or low-pass WGS. These methods impose limits on the resolution, accuracy, or flexibility of experiments.” She added, “With our eWGS solution, researchers can now get all the information they need without compromising on cost or data, enabling our customers to push new boundaries in trait selection, breeding and other applications.” (Source – Business Wire) About Twist Bioscience Corporation Founded in 2013, Twist Bioscience is a leading synthetic biology and genomics firm that has created a proprietary DNA synthesis platform to industrialize biological engineering. It assists researchers in the Life Sciences who are transforming the world for the better. Scientists from several sectors, including health, agriculture, data storage and industrial chemicals, employ its oligo pools, synthetic genes, and NGS target enrichment to improve human lives and the planet's sustainability. Its technology eliminates inefficiencies and enables cost-effective, high-throughput, quick, accurate DNA synthesis and sequencing. The company provides both the quantity and quality that researchers need to quickly capitalize on future prospects.

Read More


Ligand’s Partner Travere Therapeutics Receives Accelerated Approval of FILSPARI™ by FDA

Ligand Pharmaceuticals | February 21, 2023

In a recent announcement by biopharmaceutical firm, Ligand Pharmaceuticals, the U.S. Food and Drug Administration (FDA) has given accelerated approval for FILSPARITM (sparsentan). This will be helpful in treating adults with primary IgAN condition who are at risk of rapid disease progression, typically defined as a urine protein-to-creatinine ratio (UPCR) of less than 1.5 g/g. FILSPARI, a once-daily oral medicine, is the first and only non-immunosuppressive therapy authorized for the treatment of IgAN. Two critical pathways are selectively targeted of IgAN (endothelin-1 and angiotensin II) to check disease progression. Up to 150,000 Americans may have the rare kidney illness IgAN, which is the main cause of kidney failure brought on by glomerular disease. Among these patients, it is predicted that 30,000 to 50,000 can be treated using the indication that has received accelerated approval. Travere has stated that it anticipates FILSPARI to be available from February 27, 2023, and it will offer a thorough patient support program all the way through the patient's therapeutic journey. Eric Dube, Ph.D., President and CEO of Travere Therapeutics, said, “The accelerated approval of FILSPARI is a significant milestone on our path to advancing a transformative treatment for the IgA nephropathy community.” He further added, “As a first-of-its-kind, non-immunosuppressive therapy, we believe FILSPARI has the potential to ultimately become the new standard of care for IgA nephropathy and offer hope to those living with this condition who until now have had few treatment options. We are grateful to the patients, caregivers, clinical trial investigators, healthcare providers, and advocates who have worked alongside us to develop this innovative first-in-class therapy.” (Source – Business Wire) About Ligand Pharmaceuticals Ligand Pharmaceuticals creates or acquires technologies that aid in the discovery and development of drugs by pharmaceutical firms. The company’s business model generates value for stockholders by offering a diverse portfolio of biotech and pharmaceutical product income streams, that are underpinned by an effective and low corporate cost structure.

Read More